Targeted Medical Pharma (OTCMKTS:TRGM) & Unicycive Therapeutics (NASDAQ:UNCY) Financial Review

Unicycive Therapeutics (NASDAQ:UNCY) and Targeted Medical Pharma (OTCMKTS:TRGM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Institutional and Insider Ownership

40.4% of Unicycive Therapeutics shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by insiders. Comparatively, 69.2% of Targeted Medical Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Unicycive Therapeutics and Targeted Medical Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	N/A	-29.88%
Targeted Medical Pharma	N/A	N/A	N/A

Valuation and Earnings

This table compares Unicycive Therapeutics and Targeted Medical Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	99.79	-$30.54 million	($0.97)	-0.67
Targeted Medical Pharma	N/A	N/A	N/A	N/A	N/A

Targeted Medical Pharma has lower revenue, but higher earnings than Unicycive Therapeutics.

Analyst Ratings

This is a breakdown of current ratings for Unicycive Therapeutics and Targeted Medical Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	0	0	4	1	3.20
Targeted Medical Pharma	0	0	0	0	0.00

Unicycive Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 741.36%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Targeted Medical Pharma.

Summary

Unicycive Therapeutics beats Targeted Medical Pharma on 6 of the 8 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Targeted Medical Pharma

Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers' compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.